先进混合闭环疗法与标准胰岛素治疗在1型糖尿病产妇产时及产后早期的比较:CRISTAL随机对照试验的二次观察性分析
CRISTAL试验纳入95例1型糖尿病孕妇,随机分入MiniMed 780G先进混合闭环(AHCL)组或标准胰岛素治疗组。本预设二次观察性分析显示,产时继续AHCL者目标范围内时间高于标准治疗组(71.5% vs 63.1%,P=0.030),产后早期两组血糖控制相似,两组均无严重低血糖或糖尿病酮症酸中毒。
要点
- 产时AHCL组目标范围内时间3.5-7.8 mmol/L为71.5%,标准治疗组为63.1%(P=0.030)。
- 产时AHCL组高于范围时间>7.8 mmol/L为27.3%,标准治疗组为35.3%(P=0.054)。
- 产后早期AHCL组与标准治疗组3.9-10.0 mmol/L范围内时间分别为86.8%与83.8%(P=0.124)。
核心结论
- AHCL在产时及产后早期能有效维持严格血糖控制,并可在胰岛素需求快速变化期间安全继续使用。
研究设计与样本
- CRISTAL为在比利时和荷兰开展的双臂、开放标签、随机对照试验,将95例1型糖尿病孕妇按1:1分配至MiniMed 780G AHCL系统(n=46)或标准胰岛素治疗(n=49)。
- 本预设二次观察性分析比较原AHCL组中产时继续AHCL(n=27)和/或产后早期继续AHCL(n=37,直至出院)者与原标准胰岛素治疗组中产时(n=45)和/或产后早期(n=34)使用标准胰岛素治疗者的血糖控制与安全性差异。
主要发现
- 完成试验的AHCL组43例和标准胰岛素治疗组46例中,AHCL组27例(62.8%)产时继续AHCL,标准胰岛素治疗组45例(97.8%)产时继续标准胰岛素治疗。
- 与标准胰岛素治疗相比,产时AHCL与更多3.5-7.8 mmol/L目标范围内时间相关(71.5 ± 17.7% vs 63.1 ± 17.0%,P = 0.030)。
- 产时AHCL组高于范围>7.8 mmol/L时间数值上低于标准治疗组(27.3 ± 17.4% vs 35.3 ± 17.5%,P = 0.054)。
- 产时AHCL组低于范围<3.5 mmol/L时间未增加(1.1 ± 2.4% vs 1.5 ± 2.3%,P = 0.146)。
- 产后早期,随机分配至AHCL的37例(86.0%)继续AHCL,胰岛素与碳水化合物比值中位增加67%(四分位距-14至126)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine efficacy and safety of intrapartum and early postpartum advanced hybrid closed-loop (AHCL) therapy compared with standard insulin therapy in pregnant women with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: CRISTAL was a double-arm, open-label, randomized controlled trial performed in Belgium and the Netherlands that assigned 95 pregnant participants with T1D 1:1 to a MiniMed 780G AHCL system (n = 46) or standard insulin therapy (n = 49). This prespecified, secondary observational analysis focused on differences in glycemic control and safety outcomes between participants from the original AHCL group who continued AHCL intrapartum (n = 27) and/or early postpartum (n = 37, until hospital discharge) and those from the original standard insulin therapy group using standard insulin therapy intrapartum (n = 45) and/or early postpartum (n = 34). RESULTS: Of the 43 and 46 participants in the AHCL and standard insulin therapy groups, respectively, completing the trial, 27 (62.8%) in the AHCL group continued AHCL and 45 in the standard insulin therapy group (97.8%) continued standard insulin therapy intrapartum. Compared with standard insulin therapy, intrapartum AHCL was associated with more time in range 3.5-7.8 mmol/L (71.5 ± 17.7% vs. 63.1 ± 17.0%, P = 0.030) and numerically lower time above range >7.8 mmol/L (27.3 ± 17.4% vs. 35.3 ± 17.5%, P = 0.054), without increases in time below range <3.5 mmol/L (1.1 ± 2.4% vs. 1.5 ± 2.3%, P = 0.146). Early postpartum, 37 (86.0%) participants randomized to AHCL continued AHCL, with a median increase in insulin-to-carbohydrate ratios of 67% (interquartile range -14 to 126). Similar tight glycemic control (3.9-10.0 mmol/L: 86.8 ± 6.7% vs. 83.8 ± 8.1%, P = 0.124) was observed with AHCL versus standard insulin therapy. No severe hypoglycemia or diabetic ketoacidosis was reported in either group. CONCLUSIONS: AHCL is effective in maintaining tight glycemic control intrapartum and early postpartum and can be safely continued during periods of rapidly changing insulin requirements.
引用
- Beunen K, Gillard P, Van Wilder N, et al. Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial. Diabetes Care. 2024. PMID: 39331059. doi:10.2337/dc24-1320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。